Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug
Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
News February 11
Latest In: Epidiolex
Cannabinoid-based medicine Epidiolex approved for sale in Canada
Canada's federal health regulator has approved Jazz Pharmaceuticals Canada's cannabinoid-based medicine Epidiolex as an adjunctive therapy for certain…
News November 30
Charlotte’s Web, BAT subsidiary seek FDA approval for hemp drug
Colorado-based CBD and hemp company Charlotte's Web Holdings and a British American Tobacco subsidiary are teaming up to seek…
News April 6
Lawsuit: Generic drugmakers infringed on Epidiolex cannabis drug patents
Global pharma giant Jazz Pharmaceuticals filed a lawsuit alleging that a list of generic drug companies infringed on…
News January 9
Top CBD companies experience market share drop as online sales soften
The largest CBD companies in the U.S. experienced declining market share in the second quarter, as the return…
News August 31
DEA prevails in hemp extract fight that one judge calls ‘ridiculous’
Low-THC hemp extracts become illegal marijuana the moment they exceed o.3% THC, a federal appeals court ruled, dismissing a…
News June 13
Court tosses Canopy cannabis patent infringement lawsuit against GW Pharma
A Texas court has dismissed a lawsuit brought by Canadian cannabis producer Canopy Growth against GW Pharmaceuticals, although…
News March 2
Denmark medical cannabis sales post a positive quarter thanks to Epidiolex
Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the…
News January 7
Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement
Canadian cannabis producer Canopy Growth Corp. is suing Britain's GW Pharmaceuticals in U.S. federal court, alleging that GW…
News December 23Featured
Latest Sponsored
